Meeting Coverage
ESMO
European Society for Medical Oncology
Latest ESMO Meeting Coverage
Time to radiographic progression doubled with 177Lu-PSMA-617
Amivantamab-based regimens improved oncologic outcomes, but with more side effects
Adjuvant alectinib reduces disease-free survival hazard by 76%
Still some unanswered questions about benefit over other drug regimens, expert says
After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus
PFS doubled and OS improved, driven by mismatch repair-deficient disease
Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy
Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care
Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses
Strategies involving immunotherapy, induction chemo move the needle for first time in decades
Two randomized studies demonstrate significantly improved PFS against standard regimens
Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy
Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation
Durvalumab plus olaparib, or alone, paired with chemo boosts PFS in DUO-E trial
Latest Oncology/Hematology Meeting Coverage
-
SABCS Video Pearls: Metastatic Breast Cancer: San Antonio Breast Cancer Symposium
December 2023
-
SABCS Future Focus: Future Focus from the San Antonio Breast Cancer Symposium
December 2023
-
SABCS Video Pearls: Video Pearls from the San Antonio Breast Cancer Symposium
December 2023
-
SABCS: San Antonio Breast Cancer Symposium
December 2023